Literature DB >> 9350587

Serum hepatocyte growth factor as a possible indicator of arteriosclerosis.

M Nishimura1, M Ushiyama, A Nanbu, K Ohtsuka, H Takahashi, M Yoshimura.   

Abstract

OBJECTIVE: To investigate the possible involvement of hepatocyte growth factor in arteriosclerotic lesions, by studying the relationship between serum concentrations of hepatocyte growth factor and grades of retinal arteriosclerosis.
METHODS: We measured the blood pressure, body mass index, serum concentrations of total cholesterol, high-density lipoprotein cholesterol, triglycerides, creatinine, uric acid, total protein, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, gamma-glutamyltranspeptidase, alkaline phosphatase, and hepatocyte growth factor, erythrocyte counts, hemoglobin concentration, and hematocrit levels of 112 adults. Serum concentrations of hepatocyte growth factor were measured by a specific enzyme-linked immunosorbent assay. For each subject, photographs of both optic fundi were taken, and the grade of arteriosclerotic changes in the retinal arteries was evaluated according to Scheie's classification.
RESULTS: Individuals with more advanced grades of arteriosclerotic changes had higher serum hepatocyte growth factor values (grade 0, 0.056 +/- 0.004 ng/ml, n = 86; grade 1, 0.132 +/- 0.026 ng/ml, n = 17, P < 0.01, versus grade 0; grade 2-3, 0.271 +/- 0.023 ng/ml, n = 9, P < 0.01, versus grades 0 and 1). The serum hepatocyte growth factor concentrations were also correlated significantly to the serum uric acid concentrations (r = 0.230, P = 0.015) and erythrocyte counts (r = 0.299, P = 0.001), but not to the systolic and diastolic blood pressures, and other physical and humoral parameters.
CONCLUSIONS: Serum hepatocyte growth factor levels are thought to indicate the presence or development of arteriosclerotic lesions and may be a useful biochemical parameter for estimating the development of systemic arteriosclerosis irrespective of blood pressure levels.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9350587     DOI: 10.1097/00004872-199715100-00011

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  7 in total

1.  Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus.

Authors:  K Shinoda; S Ishida; S Kawashima; T Wakabayashi; T Matsuzaki; M Takayama; K Shinmura; M Yamada
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

2.  Production of hepatocyte growth factor during acute myocardial infarction.

Authors:  Y Zhu; Y Hojo; U Ikeda; K Shimada
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

3.  Prognostic tools at hospital arrival in acute myocardial infarction: copeptin and hepatocyte growth factor.

Authors:  María-Consuelo Pintado; Lara Maceda; María Trascasa; Ignacio Arribas; Raúl De Pablo
Journal:  Egypt Heart J       Date:  2022-04-28

Review 4.  Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus.

Authors:  Hiroyuki Konya; Masayuki Miuchi; Kahori Satani; Satoshi Matsutani; Taku Tsunoda; Yuzo Yano; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  World J Diabetes       Date:  2014-10-15

5.  Association of serum hepatocyte growth factor with pericardial fat volume in patients with coronary artery disease.

Authors:  Jingning Liu; Zhengxia Liu; Shikun Cai; Peng Lu; Xiang Lu; Gang Peng
Journal:  Int J Clin Exp Med       Date:  2015-05-15

6.  Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria.

Authors:  Bernt Johan von Scholten; Henrik Reinhard; Tine W Hansen; Jens Oellgaard; Hans-Henrik Parving; Peter K Jacobsen; Peter Rossing
Journal:  Diabetologia       Date:  2016-03-31       Impact factor: 10.122

7.  Hepatocyte growth factor predicts failure of Fontan circulation.

Authors:  Takuro Kojima; Moe Taki; Koichi Toda; Shota Muraji; Shigeki Yoshiba; Toshiki Kobayshi; Naokata Sumitomo
Journal:  ESC Heart Fail       Date:  2020-09-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.